189 related articles for article (PubMed ID: 15225793)
1. Paget's disease-a VDR coactivator disease?
Kurihara N; Ishizuka S; Demulder A; Menaa C; Roodman GD
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):321-5. PubMed ID: 15225793
[TBL] [Abstract][Full Text] [Related]
2. Role of TAFII-17, a VDR binding protein, in the increased osteoclast formation in Paget's Disease.
Kurihara N; Reddy SV; Araki N; Ishizuka S; Ozono K; Cornish J; Cundy T; Singer FR; Roodman GD
J Bone Miner Res; 2004 Jul; 19(7):1154-64. PubMed ID: 15176999
[TBL] [Abstract][Full Text] [Related]
3. 1,25-Dihydroxyvitamin D3 hypersensitivity of osteoclast precursors from patients with Paget's disease.
Menaa C; Barsony J; Reddy SV; Cornish J; Cundy T; Roodman GD
J Bone Miner Res; 2000 Feb; 15(2):228-36. PubMed ID: 10703924
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D antagonist, TEI-9647, inhibits osteoclast formation induced by 1alpha,25-dihydroxyvitamin D3 from pagetic bone marrow cells.
Ishizuka S; Kurihara N; Miura D; Takenouchi K; Cornish J; Cundy T; Reddy SV; Roodman GD
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):331-4. PubMed ID: 15225795
[TBL] [Abstract][Full Text] [Related]
5. (23S)-25-Dehydro-1{alpha}-hydroxyvitamin D3-26,23-lactone, a vitamin D receptor antagonist that inhibits osteoclast formation and bone resorption in bone marrow cultures from patients with Paget's disease.
Ishizuka S; Kurihara N; Reddy SV; Cornish J; Cundy T; Roodman GD
Endocrinology; 2005 Apr; 146(4):2023-30. PubMed ID: 15618361
[TBL] [Abstract][Full Text] [Related]
6. Cell biology of Paget's disease.
Reddy SV; Menaa C; Singer FR; Demulder A; Roodman GD
J Bone Miner Res; 1999 Oct; 14 Suppl 2():3-8. PubMed ID: 10510206
[TBL] [Abstract][Full Text] [Related]
7. Role of ATF7-TAF12 interactions in the vitamin D response hypersensitivity of osteoclast precursors in Paget's disease.
Teramachi J; Hiruma Y; Ishizuka S; Ishizuka H; Brown JP; Michou L; Cao H; Galson DL; Subler MA; Zhou H; Dempster DW; Windle JJ; Roodman GD; Kurihara N
J Bone Miner Res; 2013 Jun; 28(6):1489-500. PubMed ID: 23426901
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D receptor, oestrogen receptor-alpha and calcium-sensing receptor genotypes, bone mineral density and biochemical markers in Paget's disease of bone.
Donáth J; Speer G; Poór G; Gergely P; Tabák A; Lakatos P
Rheumatology (Oxford); 2004 Jun; 43(6):692-5. PubMed ID: 14997007
[TBL] [Abstract][Full Text] [Related]
9. Experimental models of Paget's disease.
Kurihara N; Zhou H; Reddy SV; Garcia Palacios V; Subler MA; Dempster DW; Windle JJ; Roodman GD
J Bone Miner Res; 2006 Dec; 21 Suppl 2():P55-7. PubMed ID: 17229020
[TBL] [Abstract][Full Text] [Related]
10. Etiology of Paget's disease and osteoclast abnormalities.
Reddy SV
J Cell Biochem; 2004 Nov; 93(4):688-96. PubMed ID: 15389972
[TBL] [Abstract][Full Text] [Related]
11. LXXLL peptide mimetics as inhibitors of the interaction of vitamin D receptor with coactivators.
Mita Y; Dodo K; Noguchi-Yachide T; Miyachi H; Makishima M; Hashimoto Y; Ishikawa M
Bioorg Med Chem Lett; 2010 Mar; 20(5):1712-7. PubMed ID: 20144545
[TBL] [Abstract][Full Text] [Related]
12. Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone.
Menaa C; Reddy SV; Kurihara N; Maeda H; Anderson D; Cundy T; Cornish J; Singer FR; Bruder JM; Roodman GD
J Clin Invest; 2000 Jun; 105(12):1833-8. PubMed ID: 10862799
[TBL] [Abstract][Full Text] [Related]
13. Bone stromal cells in pagetic bone and Paget's sarcoma express RANKL and support human osteoclast formation.
Sun SG; Lau YS; Itonaga I; Sabokbar A; Athanasou NA
J Pathol; 2006 May; 209(1):114-20. PubMed ID: 16482498
[TBL] [Abstract][Full Text] [Related]
14. Osteoclasts expressing the measles virus nucleocapsid gene display a pagetic phenotype.
Kurihara N; Reddy SV; Menaa C; Anderson D; Roodman GD
J Clin Invest; 2000 Mar; 105(5):607-14. PubMed ID: 10712432
[TBL] [Abstract][Full Text] [Related]
15. Expression of measles virus nucleocapsid protein in osteoclasts induces Paget's disease-like bone lesions in mice.
Kurihara N; Zhou H; Reddy SV; Garcia Palacios V; Subler MA; Dempster DW; Windle JJ; Roodman GD
J Bone Miner Res; 2006 Mar; 21(3):446-55. PubMed ID: 16491293
[TBL] [Abstract][Full Text] [Related]
16. [The correlation between the serum levels of osteocalcin and 24,25-dihydroxyvitamin D in Paget's disease of bone].
Castro Errecarborde N; de la Piedra Gordo C; Rapado Errazti A
An Med Interna; 1990 Jun; 7(6):286-90. PubMed ID: 2102732
[TBL] [Abstract][Full Text] [Related]
17. Management of Paget's disease of bone.
Langston AL; Ralston SH
Rheumatology (Oxford); 2004 Aug; 43(8):955-9. PubMed ID: 15187244
[TBL] [Abstract][Full Text] [Related]
18. Studies in Paget's disease and their relevance to oncology.
Roodman GD
Semin Oncol; 2001 Aug; 28(4 Suppl 11):15-21. PubMed ID: 11544571
[TBL] [Abstract][Full Text] [Related]
19. 1,25-Dihydroxyvitamin D3 up-regulates the renal vitamin D receptor through indirect gene activation and receptor stabilization.
Healy KD; Frahm MA; DeLuca HF
Arch Biochem Biophys; 2005 Jan; 433(2):466-73. PubMed ID: 15581603
[TBL] [Abstract][Full Text] [Related]
20. Apoptotic gene expression in Paget's disease: a possible role for Bcl-2.
Brandwood CP; Hoyland JA; Hillarby MC; Berry JL; Davies M; Selby PL; Mee AP
J Pathol; 2003 Nov; 201(3):504-12. PubMed ID: 14595764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
